You are here

Article Text

Article menu
Download PDFPDF
Therapeutics/Prevention
Systematic review
Staphylococcus aureus bacteraemia management: where do we stand and where are we going?
  1. Pamela A Moise1,
  2. George Sakoulas2
  1. 1Department of Medical Affairs, Cubist Pharmaceuticals, Lexington, Massachusetts, USA;
  2. 2University of California San Diego, La Jolla, California, USA
  1. Correspondence to : Dr Pamela A Moise, Department of Medical Affairs, Cubist Pharmaceuticals, 65 Hayden Avenue, Lexington, MA 02421, USA; Pamela.Moise{at}cubist.com

https://doi.org/10.1136/ebmed-2014-110122

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Holland TL, Arnold C, Fowler VG Jr.. Clinical management of Staphylococcus aureus bacteraemia: a review. JAMA 2014;312:1330–41.OpenUrlCrossRefPubMedWeb of Science

    Context

    Staphylococcus aureus is a common cause of bacteraemia from hospitalised patients in the USA. It is also a very prevalent bacterial pathogen among clinical isolates from outpatients. Despite our technological innovations within and outside of the practice of science and medicine in the past two decades, mortality due to S. aureus bacteremia (SaB) has not changed during this time, remaining at about 20%. The goals of this review were to determine which patients with SaB need transesophageal echocardiography (TEE) and to determine the optimal antibiotic regimen.

    Methods

    This largely narrative review by Holland and colleagues provides a thorough literature review on the clinical data on which therapeutic and diagnostic standards in …

    View Full Text

    Footnotes

    • Contributors PAM and GS were involved in the drafting and editing the commentary, and have approved the final submitted version.

    • Funding GS has received research grant support to his institution from Forrest and speaking honoraria from Cubist and Forest.

    • Competing interests PM is an employer and shareholder of Cubist Pharmaceuticals.

    • Provenance and peer review Commissioned; internally peer reviewed.